Otonomy reports positive results with hearing loss candidate

A former Novo Ventures-owned biotech firm, Otonomy, has announced that a full phase II trial of its hearing loss drug candidate will take place this year after having just publicized positive results from a preceding phase IIa study.
Photo: Emrah Gurel/AP/Ritzau Scanpix
Photo: Emrah Gurel/AP/Ritzau Scanpix
by christian bundgaard, translated by daniel pedersen

Biotech firm Otonomy, listed in the US, has scored its first top-line results from clinical studies of the candidate OTO-413, a potential hearing loss treatment, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading